Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6

The objectives of this study were the determination of CA 125 in the cytosol of healthy and carcinomatous ovarian tissue by immunoanalysis, analysis of its correlation with the biological characteristics of ovarian carcinoma, determination of serum CA 125 levels, and study of the prognostic value of the marker in cytosol. The levels of the marker depend not only on the tumor's production rate, so its determination in tissue can indicate more accurately if the tumor is a producer of the marker and establish its value for the prognosis of the disease. Determination of CA 125 in tissue was performed by immunoanalysis in 50 ovarian epithelial cancer samples, 13 benign pathology samples and 32 healthy ovary samples. The presurgical serum level of the marker was also obtained. The correlation between the CA 125 level in the cytosol and the different biological characteristics of the ovarian carcinoma, the serum levels of the marker and survival were analyzed. The CA 125 level proved to be higher in malignant tissue (p<0.0001). There was a significant association between the tissue marker and histological type (high CA 125 was associated with serous and endometrioid tumors) and between the marker and survival. No relation with stage was found. There was a correlation between the CA 125 level in the cytosol and serum, both variables being dependent, with a correlation coefficient of 0.44. This good correlation speaks in favor of the usefulness of CA 125 determination in serum in the follow-up of ovarian cancer. Tumors having high tissue expression of CA 125 were found to have a double relative risk of death, independently of tumor stage.

Download Full-text

Key biomarkers within the colorectal cancer related inflammatory microenvironment

Scientific Reports ◽

10.1038/s41598-021-86941-5 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Valentin Calu ◽

Adriana Ionescu ◽

Loredana Stanca ◽

Ovidiu Ionut Geicu ◽

Florin Iordache ◽

...

Keyword(s):

Colorectal Cancer ◽

Tumor Staging ◽

Pearson Correlation ◽

Tumor Resection ◽

Correlation Coefficients ◽

Tumor Stage ◽

Magnetic Bead ◽

Tissue Expression ◽

Tissue Samples ◽

Inflammatory Microenvironment

AbstractTherapeutic approaches focused on the inflammatory microenvironment are currently gaining more support, as biomolecules involved in the inflammatory colorectal cancer (CRC) tumor microenvironment are being explored. We analyzed tumor and paired normal tissue samples from CRC patients (n = 22) whom underwent tumor resection surgery. We assessed 39 inflammation-involved biomolecules (multiplex magnetic bead-based immunoassay), CEA and CA19-9 (ELISA assay) and the tissue expression levels of occludin and also pErk, STAT1 and STAT3 transcriptional factors (western blot). Tumor staging has been established by histopathological evaluation of HE stained tumor tissue sections. We report 32 biomarkers displaying statistically significant differences in tumor vs. control. Additionally, positive statistical biomarker correlations were found between MMP2–IL8 and BAFF–IL8 (Pearson correlation coefficients > 0.751), while APRIL–MMP2, APRIL–BAFF and APRIL–IL8 were negatively correlated (correlation coefficients < − 0.650). While APRIL, BAFF, IL8 and MMP2 did not modulate with tumor stage, they were inversely related to the immune infiltrate level and CD163 tissue expression. We conclude that the significantly decreased APRIL and increased BAFF, IL8 and MMP2 expression were tumor-specific and deserve consideration in the development of new treatments. Also, the positive correlation between Chitinase 3-like 1 and IL8 (0.57) or MMP2 (0.50) suggest a role in tumor growth and metastasis pathways.

Download Full-text

Assessment of Serum Levels of the Adipocytokine Chemerin in Colorectal Cancer Patients

Journal of Medical Biochemistry ◽

10.1515/jomb-2017-0062 ◽

2018 ◽

Vol 37 (3) ◽

pp. 313-319 ◽

Cited By ~ 9

Author(s):

Manal M. Alkady ◽

Phebe L. Abdel-Messeih ◽

Neveen M. Nosseir

Keyword(s):

Colorectal Cancer ◽

Characteristic Curve ◽

Serum Levels ◽

Tumor Stage ◽

Carbohydrate Antigen ◽

Cancer Cell Growth ◽

Reactive Protein ◽

Stage Progression ◽

Embryonic Antigen ◽

Colorectal Cancer Patients

Summary Colorectal cancer (CRC) is one of the most common cancers worldwide. The tumor microenvironment is very important for determining cancer cell growth and spreading. Chemerin, a newly identified adipokine secreted by adipose tissue, is known to be associated with obesity, metabolic syndrome, and insulin resistance. The present study was carried out to investigate the association between serum levels of chemerin and colorectal cancer. Thirty-two patients with colorectal cancer aged 57.6±6.5 years, and twenty age, sex and BMI matched healthy controls were included in the study. Serum che me rin levels were determined using enzyme linked immuno sorbent assay. C-reactive protein (CRP) levels were determined using a turbidimetric immunoassay. Carcino embryonic antigen (CEA) and carbohydrate antigen (CA 19-9) were measured by radioimmunoassay. Chemerin levels were found to be significantly higher in patients relative to the controls (P<0.001) and gradually increased with the TNM tumor stage progression. The mean CRP, CEA and CA 19-9 levels were also significantly higher in patients (P<0.001). There was a significant correlation between the serum levels of chemerin and the other measured parameters in CRC patients. The area under receiver operating characteristic curve (ROC) for serum chemerin was 1 at a cut-off value ≥ 161.5 with 100% sensitivity and 100% specificity. Conclusions: The observed results suggest that chemerin may have a potential role in the pathogenesis and progression of colorectal malignancy and may be a good biomarker of colorectal cancer and stage progression.

Download Full-text

Serum Levels of Fatty Acid Synthase in Colorectal Cancer Patients Are Associated with Tumor Stage

Journal of Gastrointestinal Cancer ◽

10.1007/s12029-011-9300-2 ◽

2011 ◽

Vol 43 (3) ◽

pp. 508-511 ◽

Cited By ~ 20

Author(s):

Maria Notarnicola ◽

Valeria Tutino ◽

Menotti Calvani ◽

Dionigi Lorusso ◽

Vito Guerra ◽

...

Keyword(s):

Colorectal Cancer ◽

Fatty Acid ◽

Cancer Patients ◽

Fatty Acid Synthase ◽

Serum Levels ◽

Tumor Stage ◽

Colorectal Cancer Patients

Download Full-text

HMGA2 rs968697 T>C Polymorphism is Associated With The Risk of Colorectal Cancer

10.21203/rs.3.rs-159922/v1 ◽

2021 ◽

Author(s):

Zhidan Li ◽

Jiaojiao Yang ◽

Shulong Zhang ◽

Xiaoting Wang ◽

Xueren Gao

Keyword(s):

Colorectal Cancer ◽

In Silico Analysis ◽

Tumor Stage ◽

Tissue Expression ◽

Healthy Individuals ◽

Quantitative Real Time Pcr ◽

Pcr Technology ◽

And Gender ◽

Running Head ◽

Silico Analysis

Abstract Background: Recently, a genetic polymorphism (rs968697 T>C) in HMGA2 gene has been reported to be associated with hepatoblastoma risk. However, no studies reported the effect of the polymorphism on the risk of colorectal cancer (CRC). The study aimed to explore whether rs968697 polymorphism had a significant impact on CRC risk. Methods: A total of 500 CRC patients and 500 age and gender matched healthy individuals were genotyped by Sanger sequencing. Quantitative real-time PCR technology was used to detect the relative expression of HMGA2 gene in 30 pairs of primary CRC and adjacent non-cancerous tissues.Results: HMGA2 rs968697 polymorphism was significantly associated with CRC risk (CC vs. TT: OR=0.20, 95%CI=0.06-0.70, P=0.01; (CC+CT) vs. TT: OR=0.71, 95%CI=0.53-0.96, P=0.02; CC vs. (CT+TT): OR=0.21, 95%CI=0.06-0.73, P=0.01; C vs. T: OR=0.67, 95%CI=0.51-0.89, P<0.01). The analysis based on tumor stage indicated that HMGA2 rs968697 polymorphism was significantly associated with CRC tumor stage. In addition, the genotype-tissue expression showed that the rs968697 polymorphism was related to HMGA2 gene expression. The in silico analysis showed that rs968697 polymorphism located in the promoter region of HMGA2 gene could affect the binding of transcription factors. Conclusion: Our study suggested that HMGA2 rs968697 polymorphism was associated with CRC risk and might serve as a reliable biomarker to detect CRC risk. Running head: HMGA2 rs968697 T>C polymorphism and colorectal cancer

Download Full-text

Clinical significance of circulating tumor cell related markers in patients with epithelial ovarian cancer before and after adjuvant chemotherapy

Scientific Reports ◽

10.1038/s41598-021-88780-w ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Meysam Yousefi ◽

Sara Rajaie ◽

Vahideh Keyvani ◽

Somayeh Bolandi ◽

Malihe Hasanzadeh ◽

...

Keyword(s):

Ovarian Cancer ◽

Adjuvant Chemotherapy ◽

Epithelial Ovarian Cancer ◽

Clinical Significance ◽

Therapy Response ◽

Serum Levels ◽

Circulating Tumor Cell ◽

Tumor Stage ◽

Disease Stage ◽

Before And After

AbstractCirculating tumor cells (CTCs) have recently been considered as new prognostic and diagnostic markers for various human cancers; however, their significance in epithelial ovarian cancer (EOC) remains to be elucidated. In this study, using quantitative real-time PCR, we evaluated the expression of EPCAM, MUC1, CEA, HE4 and CA125 mRNAs, as putative markers of CTCs, in the blood of 51 EOC patients before and/or after adjuvant chemotherapy. Our results demonstrated that, before chemotherapy, the expression of EPCAM, MUC1, CEA and HE4 mRNAs were correlated to each other. CEA expression was correlated with tumor stage (r = 0.594, p = 0.000) before chemotherapy, whereas its expression after chemotherapy was correlated with serum levels of CA125 antigen (r = 0.658, p = 0.000). HE4 mRNA showed the highest sensitivity both before and after chemotherapy (82.98% and 85.19%, respectively) and the persistence of this marker after chemotherapy was associated with advanced disease stage. The expression of CA125 mRNA had negative correlation with the other markers and with tumor stage and therapy response (evaluated by the measurement of serum CA125 antigen). Collectively, our results indicated a better clinical significance of tumor-specific markers (CEA and HE4 mRNAs) compared to epithelial-specific markers (EPCAM and MUC1 mRNAs).

Download Full-text

Are there sex differences among colorectal cancer patients in treatment and survival? A Swiss cohort study

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-021-03557-y ◽

2021 ◽

Vol 147 (5) ◽

pp. 1407-1419

Author(s):

Manuela Limam ◽

Katarina Luise Matthes ◽

Giulia Pestoni ◽

Eleftheria Michalopoulou ◽

Leonhard Held ◽

...

Keyword(s):

Colorectal Cancer ◽

Regression Models ◽

Proportional Hazards ◽

Treatment Decision ◽

Tumor Stage ◽

Primary Treatment ◽

Cox Proportional Hazards ◽

Men And Women ◽

Logistic Regression Models ◽

Comorbidity Index

Abstract Background Colorectal cancer (CRC) is among the three most common incident cancers and causes of cancer death in Switzerland for both men and women. To promote aspects of gender medicine, we examined differences in treatment decision and survival by sex in CRC patients diagnosed 2000 and 2001 in the canton of Zurich, Switzerland. Methods Characteristics assessed of 1076 CRC patients were sex, tumor subsite, age at diagnosis, tumor stage, primary treatment option and comorbidity rated by the Charlson Comorbidity Index (CCI). Missing data for stage and comorbidities were completed using multivariate imputation by chained equations. We estimated the probability of receiving surgery versus another primary treatment using multivariable binomial logistic regression models. Univariable and multivariable Cox proportional hazards regression models were used for survival analysis. Results Females were older at diagnosis and had less comorbidities than men. There was no difference with respect to treatment decisions between men and women. The probability of receiving a primary treatment other than surgery was nearly twice as high in patients with the highest comorbidity index, CCI 2+, compared with patients without comorbidities. This effect was significantly stronger in women than in men (p-interaction = 0.010). Survival decreased with higher CCI, tumor stage and age in all CRC patients. Sex had no impact on survival. Conclusion The probability of receiving any primary treatment and survival were independent of sex. However, female CRC patients with the highest CCI appeared more likely to receive other therapy than surgery compared to their male counterparts.

Download Full-text

PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC

Breast Disease ◽

10.3233/bd-201049 ◽

2021 ◽

pp. 1-9

Author(s):

Parvaneh Yazdanpanah ◽

Ali Alavianmehr ◽

Abbas Ghaderi ◽

Ahmad Monabati ◽

Mehdi Montazer ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Serum Levels ◽

Tumor Stage ◽

Serum Samples ◽

Healthy Women ◽

Grade 3 ◽

Anti Tumor Activity ◽

Tnbc Subtype ◽

Cell Death Protein

BACKGROUND: Block of programmed cell death protein 1 (PD-1) interaction with its ligand, PD-L1, enhances anti-tumor activity. OBJECTIVES: We aimed to assess the association between PD-L1 expression in tumor cells and CD8+ tumor infiltrating T cells (TILs) as well as soluble (s)PD-L1 serum levels in patients with triple negative breast cancer (TNBC) compared to triple positive (TPBC). METHODS: A total of 113 tumor sections and 133 serum samples were available from 144 patients with breast cancer (72 TNBC and 72 TPBC). Dual immunohistochemistry staining was applied to determine differential PD-L1 expression in tumor cells and CD8+ TILs. Soluble PD-L1 serum levels were also evaluated in patients compared to 40 healthy women by ELISA method. RESULTS: Despite TPBC patients which were mostly grades 1/2, TNBC patients were grade 3 (72% versus 66.7%, P < 0.001). Most of the TNBC patients were stages I/II, whereas most of the TPBC patients were stages III/IV (57.3% versus 68.3%,P = 0.005). There was no difference in tumor size and metastasis between TNBC and TPBC patients, although the number of involved lymph nodes was significantly more in TPBC patients (P = 0.0012). PD-L1 expression was detected in 11.5% of samples mostly in TNBC subtype and was associated with advanced grades (P = 0.039). There was no relationship between PD-L1 expression and tumor stage. PD-L1 expression in CD8+ TILs was nonsignificantly higher than tumor cells. Serum levels of sPD-L1 showed no difference between patients and healthy women. We found no correlation between PD-L1 expression in tumor lesions and serum levels of sPD-L1 in patients. CONCLUSION: PD-L1 expression was more detected in our patients with TNBC. It seems that, these patients who are resistant to standard chemotherapy regimens may get benefit from PD-L1 inhibition therapy and because of its low serum levels, sPD-L1 cannot interfere with this therapy.

Download Full-text